vTv Therapeutics Inc. (VTVT)
NASDAQ: VTVT · Real-Time Price · USD
14.96
+0.44 (3.03%)
Dec 20, 2024, 4:00 PM EST - Market closed
vTv Therapeutics Employees
vTv Therapeutics had 16 employees as of December 31, 2023. The number of employees increased by 3 or 23.08% compared to the previous year.
Employees
16
Change (1Y)
3
Growth (1Y)
23.08%
Revenue / Employee
$62,500
Profits / Employee
-$1,144,125
Market Cap
47.72M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Rapid Micro Biosystems | 193 |
Cytosorbents | 186 |
Fortress Biotech | 186 |
Omega Therapeutics | 94 |
iCAD, Inc. | 69 |
Kezar Life Sciences | 58 |
enVVeno Medical | 31 |
Nutriband | 13 |
VTVT News
- 12 days ago - CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER - PRNewsWire
- 19 days ago - vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference - GlobeNewsWire
- 4 months ago - vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold - GlobeNewsWire
- 6 months ago - vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes - GlobeNewsWire
- 7 months ago - CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING - PRNewsWire
- 8 months ago - vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update - GlobeNewsWire
- 9 months ago - CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT - PRNewsWire